Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

NHA000160

Type of data
GWAS for 555 Japanese individuals vaccinated with a HB vaccine (Heptavax)
Access criteria
Unrestricted-access
Total data volume
111 MB
File formats
  • XLSX
  • ZIP
Research
hum0136
Date published
2021-03-05
Date modified
2021-03-05
Secondary ID
hum0136.v2.hep-gwas.v1

Unrestricted-access files linked to this dataset

Download the URL list
FileLabelSizeCopy URL
header_definition_hum0136.v2.hep-gwas.v1.xlsxDictionary file15.9 KB
hum0136.v2.hep-gwas.v1.zip111 MB

Analysis method

Genotyping by array

Materials and participants
555 Japanese individuals vaccinated with a HB vaccine (Heptavax)
- Low responders (n=66, HBsAb ≤ 10mIU/mL)
- Intermediate responders (n=184, 10mIU/mL < HBsAb ≤ 100mIU/mL)
- High responders (n=305, HBsAb >100mIU/mL)
  • Health status
    Healthy
  • Subject count
    555 (Individual)
  • Population
    Japanese
Sample description
DNAs extracted from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
Genotyping by array
Target
N/A
Reagent kit
Axiom 2.0 Reagent Kit
Platform
Affymetrix Axiom Genome-Wide ASI 1 Array
Reference genome
GRCh37
QC and filtering
overall call rate < 0.95, SNP call rate < 0.95,
HWE P < 0.001, MAF < 0.05, Regression P < 0.05
Analysis method
GenCall software (Genotyping Console ver. 4.2.0.26)
Variant count
I. GWAS for low responders (n=66) and responders (n=489) with Heptavax (after imputation): 279,671 SNPs (Figure 1a)
II. GWAS for low responders (n=66) and high responders (n=305) with Heptavax (after imputation): 292,028 SNPs (Figure 1b)
III. GWAS for low responders (n=66) and responders (n=489) with Heptavax (before imputation): 22,770 SNPs (Supplementary Figure 1a)
IV. GWAS for low responders (n=66) and high responders (n=305) with Heptavax (before imputation): 23,717 SNPs (Supplementary Figure 1b)
V. GWAS for low responders (n=66 + 107) and responders (n=489 + 1086) with Heptavax and Bimmugen (after imputation): 310,312 SNPs (Supplementary Figure 2a)
VI. GWAS for low responders (n=66 + 107) and high responders (n=305 + 735) with Heptavax and Bimmugen (after imputation): 317,176 SNPs (Supplementary Figure 2b)
VII. GWAS for low responders with Heptavax (n=66) and low responders with Bimmugen (n=107) (after imputation): 285,687 SNPs (Supplementary Figure 3a)
VIII. GWAS for intermediate responders with Heptavax (n=184) and intermediate responders with Bimmugen (n=351) (after imputation): 312,192 SNPs (Supplementary Figure 3b)
IX. GWAS for high responders with Heptavax (n=305) and high responders with Bimmugen (n=735) (after imputation): 321,074 SNPs (Supplementary Figure 3c)
Data use policy
NBDC data sharing policy (JGAP000001)